Structural basis for plazomicin antibiotic action and resistance.

Communications Biology
Tolou GolkarAlbert M Berghuis

Abstract

The approval of plazomicin broadened the clinical library of aminoglycosides available for use against emerging bacterial pathogens. Contrarily to other aminoglycosides, resistance to plazomicin is limited; still, instances of resistance have been reported in clinical settings. Here, we present structural insights into the mechanism of plazomicin action and the mechanisms of clinical resistance. The structural data reveal that plazomicin exclusively binds to the 16S ribosomal A site, where it likely interferes with the fidelity of mRNA translation. The unique extensions to the core aminoglycoside scaffold incorporated into the structure of plazomicin do not interfere with ribosome binding, which is analogously seen in the binding of this antibiotic to the AAC(2')-Ia resistance enzyme. The data provides a structural rationale for resistance conferred by drug acetylation and ribosome methylation, i.e., the two mechanisms of resistance observed clinically. Finally, the crystal structures of plazomicin in complex with both its target and the clinically relevant resistance factor provide a roadmap for next-generation drug development that aims to ameliorate the impact of antibiotic resistance.

References

Jun 28, 2000·Nucleic Acids Research·E CayamaF J Triana-Alonso
May 15, 2002·The EMBO Journal·Desiree H Fong, Albert M Berghuis
Sep 1, 1994·Acta Crystallographica. Section D, Biological Crystallography·UNKNOWN Collaborative Computational Project, Number 4
Jan 28, 2005·Antimicrobial Agents and Chemotherapy·Keith Poole
Feb 11, 2005·Chemical Reviews·Sophie Magnet, John S Blanchard
May 26, 2005·Protein Expression and Purification·F William Studier
Dec 22, 2005·Acta Crystallographica. Section D, Biological Crystallography·Philip Evans
Aug 8, 2006·Biochimie·A Lescoute, E Westhof
Sep 9, 2006·Science·Maria SelmerV Ramakrishnan
Jul 31, 2007·Nature Structural & Molecular Biology·Maria A BorovinskayaJamie H Doudna Cate
Feb 23, 2008·Nature Reviews. Molecular Cell Biology·Thomas A Steitz
Apr 26, 2008·Methods in Molecular Medicine·Engin H SerpersuEdward Wright
Sep 23, 2009·Acta Crystallographica. Section D, Biological Crystallography·Nigel W MoriartyPaul D Adams
Feb 4, 2010·Acta Crystallographica. Section D, Biological Crystallography·Wolfgang Kabsch
Feb 4, 2010·Acta Crystallographica. Section D, Biological Crystallography·Paul D AdamsPeter H Zwart
Apr 13, 2010·Acta Crystallographica. Section D, Biological Crystallography·P EmsleyK Cowtan
Sep 2, 2010·Antimicrobial Agents and Chemotherapy·James B AggenHeinz E Moser
Sep 14, 2010·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Maria S Ramirez, Marcelo E Tolmasky
Nov 17, 2010·The Journal of Antimicrobial Chemotherapy·D M LivermoreN Woodford
Oct 14, 2014·Molecular Cell·Yury S PolikanovPetr V Sergiev
Jun 2, 2015·New Microbes and New Infections·I RocaJ Vila
Jun 3, 2016·Cold Spring Harbor Perspectives in Medicine·Kevin M KrauseLynn E Connolly
Aug 2, 2017·Nature Reviews. Microbiology·Morten O A SommerDan I Andersson
Dec 26, 2017·The Lancet Infectious Diseases·Evelina TacconelliUNKNOWN WHO Pathogens Priority List Working Group
Mar 14, 2018·Acta Crystallographica. Section D, Structural Biology·Graeme WinterGwyndaf Evans
Apr 11, 2018·ACS Infectious Diseases·Georgina CoxGerard D Wright
Apr 18, 2018·Antimicrobial Agents and Chemotherapy·Shane J Caldwell, Albert M Berghuis
Dec 5, 2018·Pharmacotherapy·Kristy M ShaeerJonathan C Cho

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

Coot
. refine
POINTLESS
xia2
eLBOW
phenix
DIALS
XDS

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.